State strategy for the treatment of spinal muscular atrophy: a challenge for the health system in Argentina

Detalhes bibliográficos
Autor(a) principal: Carignani, Agustín
Data de Publicação: 2020
Outros Autores: Flores, Daniela Yannen
Tipo de documento: Artigo
Idioma: spa
Título da fonte: Cadernos Ibero-Americanos de Direito Sanitário (Online)
Texto Completo: https://www.cadernos.prodisa.fiocruz.br/index.php/cadernos/article/view/749
Resumo: Objective: to analyze the implementation and commercialization of high-cost drugs in the Argentine health system, taking as a reference the medical treatment of spinal muscular atrophy disease and analyze the applicable regulations, demonstrating the legislative parallelism with the Federative Republic of Brazil. Methods: a descriptive-analytical investigation was conducted to identify the criteria set out in the rules or regulations for the implementation of a high-cost medication. Results: we obtained the regulatory framework for the medication called nusinersen in Argentina and the Federative Republic of Brazil. Conclusion: with the advancement of technology, its high costs have a direct impact on the possibility of access, before which we believe that in addition to the internal negotiation tools of each country, international cooperation is a fundamental tool to transform this reality into an opportunity access.
id FIOCRUZ-3_1b2dd3b7d6375cd37c7092212e338359
oai_identifier_str oai:ojs.cadernos.prodisa.fiocruz.br:article/749
network_acronym_str FIOCRUZ-3
network_name_str Cadernos Ibero-Americanos de Direito Sanitário (Online)
repository_id_str
spelling State strategy for the treatment of spinal muscular atrophy: a challenge for the health system in ArgentinaEstrategia de Estado para el tratamiento de la atrofia muscular espinal: un desafío del sistema de salud en ArgentinaEstratégia de Estado para o tratamento da atrofia muscular espinhal: um desafio para o sistema de saúde da ArgentinaAtrofia muscular espinalCostos de los medicamentosDerecho a la saludAtrofia muscular espinalCostos de los medicamentosDerecho a la saludMuscular atrophy spinal Drug costsRight to healthObjective: to analyze the implementation and commercialization of high-cost drugs in the Argentine health system, taking as a reference the medical treatment of spinal muscular atrophy disease and analyze the applicable regulations, demonstrating the legislative parallelism with the Federative Republic of Brazil. Methods: a descriptive-analytical investigation was conducted to identify the criteria set out in the rules or regulations for the implementation of a high-cost medication. Results: we obtained the regulatory framework for the medication called nusinersen in Argentina and the Federative Republic of Brazil. Conclusion: with the advancement of technology, its high costs have a direct impact on the possibility of access, before which we believe that in addition to the internal negotiation tools of each country, international cooperation is a fundamental tool to transform this reality into an opportunity access.Objetivo: analisar a implantação e comercialização de medicamentos de alto custo no sistema de saúde argentino, tomando como referência o tratamento médico da doença atrofia muscular espinhal; e analisar a regulamentação aplicável, demonstrando o paralelismo legislativo com a República Federativa do Brasil. Metodologia: foi realizada uma pesquisa descritiva analítica, identificando os critérios previstos nas normas ou regulamentos para a implantação de um medicamento de alto custo. Resultados: obtivemos o marco regulatório do medicamento denominado nusinersen na Argentina e na República Federativa do Brasil. Conclusão: os altos custos da tecnologia impactam diretamente no seu acesso. Acreditamos que, além dos instrumentos de negociação interna de cada país, a cooperação internacional é uma ferramenta fundamental para transformar essa realidade em oportunidade de acesso.Objetivo: analizar la implementación y comercialización de medicamentos de alto costo en el sistema de salud argentino, tomando como referencia el tratamiento médico de la enfermedad de atrofia muscular espinal y analizar la normativa aplicable, demonstrando el paralelismo legislativo con la República Federativa del Brasil. Metodología: se realizó una investigación descriptiva analítica identificando los criterios plasmados en las normas ó reglamentos para la implementación de una medicación de alto costo. Resultados: logramos obtener el marco regulatorio de la medicación denominada nusinersen en Argentina y la República Federativa del Brasil. Conclusión: con el avance de la tecnología, sus altos costos impactan directamente en la posibilidad de acceso, ante lo cual creemos que además de las herramientas de negociación interna de cada país, la cooperación internacional resulta una herramienta fundamental para transformar esta realidad en una oportunidad de acceso.Fundação Oswaldo Cruz Brasília2020-12-16info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.cadernos.prodisa.fiocruz.br/index.php/cadernos/article/view/74910.17566/ciads.v9i4.749Iberoamerican Journal of Health Law; Vol. 9 No. 4 (2020): (OCT./DEC. 2020); 70-88Cuadernos Iberoamericanos de Derecho Sanitario; Vol. 9 Núm. 4 (2020): (OCT./DEC. 2020); 70-88Cadernos Ibero-Americanos de Direito Sanitário; v. 9 n. 4 (2020): (OUT./DEZ. 2020); 70-882358-18242317-839610.17566/ciads.v9i4reponame:Cadernos Ibero-Americanos de Direito Sanitário (Online)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZspahttps://www.cadernos.prodisa.fiocruz.br/index.php/cadernos/article/view/749/778Copyright (c) 2020 Agustín Carignani, Daniela Yannen Floreshttps://creativecommons.org/licenses/by-nc/4.0info:eu-repo/semantics/openAccessCarignani, AgustínFlores, Daniela YannenCarignani, AgustínFlores, Daniela YannenCarignani, AgustínFlores, Daniela Yannen2021-01-25T17:53:48Zoai:ojs.cadernos.prodisa.fiocruz.br:article/749Revistahttp://www.cadernos.prodisa.fiocruz.brPUBhttp://www.cadernos.prodisa.fiocruz.br/index.php/cadernos/oaicadernos.direitosanitario@fiocruz.br2358-18242317-8396opendoar:2021-01-25T17:53:48Cadernos Ibero-Americanos de Direito Sanitário (Online) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.none.fl_str_mv State strategy for the treatment of spinal muscular atrophy: a challenge for the health system in Argentina
Estrategia de Estado para el tratamiento de la atrofia muscular espinal: un desafío del sistema de salud en Argentina
Estratégia de Estado para o tratamento da atrofia muscular espinhal: um desafio para o sistema de saúde da Argentina
title State strategy for the treatment of spinal muscular atrophy: a challenge for the health system in Argentina
spellingShingle State strategy for the treatment of spinal muscular atrophy: a challenge for the health system in Argentina
Carignani, Agustín
Atrofia muscular espinal
Costos de los medicamentos
Derecho a la salud
Atrofia muscular espinal
Costos de los medicamentos
Derecho a la salud
Muscular atrophy spinal
Drug costs
Right to health
title_short State strategy for the treatment of spinal muscular atrophy: a challenge for the health system in Argentina
title_full State strategy for the treatment of spinal muscular atrophy: a challenge for the health system in Argentina
title_fullStr State strategy for the treatment of spinal muscular atrophy: a challenge for the health system in Argentina
title_full_unstemmed State strategy for the treatment of spinal muscular atrophy: a challenge for the health system in Argentina
title_sort State strategy for the treatment of spinal muscular atrophy: a challenge for the health system in Argentina
author Carignani, Agustín
author_facet Carignani, Agustín
Flores, Daniela Yannen
author_role author
author2 Flores, Daniela Yannen
author2_role author
dc.contributor.author.fl_str_mv Carignani, Agustín
Flores, Daniela Yannen
Carignani, Agustín
Flores, Daniela Yannen
Carignani, Agustín
Flores, Daniela Yannen
dc.subject.por.fl_str_mv Atrofia muscular espinal
Costos de los medicamentos
Derecho a la salud
Atrofia muscular espinal
Costos de los medicamentos
Derecho a la salud
Muscular atrophy spinal
Drug costs
Right to health
topic Atrofia muscular espinal
Costos de los medicamentos
Derecho a la salud
Atrofia muscular espinal
Costos de los medicamentos
Derecho a la salud
Muscular atrophy spinal
Drug costs
Right to health
description Objective: to analyze the implementation and commercialization of high-cost drugs in the Argentine health system, taking as a reference the medical treatment of spinal muscular atrophy disease and analyze the applicable regulations, demonstrating the legislative parallelism with the Federative Republic of Brazil. Methods: a descriptive-analytical investigation was conducted to identify the criteria set out in the rules or regulations for the implementation of a high-cost medication. Results: we obtained the regulatory framework for the medication called nusinersen in Argentina and the Federative Republic of Brazil. Conclusion: with the advancement of technology, its high costs have a direct impact on the possibility of access, before which we believe that in addition to the internal negotiation tools of each country, international cooperation is a fundamental tool to transform this reality into an opportunity access.
publishDate 2020
dc.date.none.fl_str_mv 2020-12-16
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.cadernos.prodisa.fiocruz.br/index.php/cadernos/article/view/749
10.17566/ciads.v9i4.749
url https://www.cadernos.prodisa.fiocruz.br/index.php/cadernos/article/view/749
identifier_str_mv 10.17566/ciads.v9i4.749
dc.language.iso.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://www.cadernos.prodisa.fiocruz.br/index.php/cadernos/article/view/749/778
dc.rights.driver.fl_str_mv Copyright (c) 2020 Agustín Carignani, Daniela Yannen Flores
https://creativecommons.org/licenses/by-nc/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2020 Agustín Carignani, Daniela Yannen Flores
https://creativecommons.org/licenses/by-nc/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Fundação Oswaldo Cruz Brasília
publisher.none.fl_str_mv Fundação Oswaldo Cruz Brasília
dc.source.none.fl_str_mv Iberoamerican Journal of Health Law; Vol. 9 No. 4 (2020): (OCT./DEC. 2020); 70-88
Cuadernos Iberoamericanos de Derecho Sanitario; Vol. 9 Núm. 4 (2020): (OCT./DEC. 2020); 70-88
Cadernos Ibero-Americanos de Direito Sanitário; v. 9 n. 4 (2020): (OUT./DEZ. 2020); 70-88
2358-1824
2317-8396
10.17566/ciads.v9i4
reponame:Cadernos Ibero-Americanos de Direito Sanitário (Online)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Cadernos Ibero-Americanos de Direito Sanitário (Online)
collection Cadernos Ibero-Americanos de Direito Sanitário (Online)
repository.name.fl_str_mv Cadernos Ibero-Americanos de Direito Sanitário (Online) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv cadernos.direitosanitario@fiocruz.br
_version_ 1798942495755730944

Registros relacionados